Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Apnimed raises $192M IPO for potential 2027 sleep apnea drug launch

In the city that never sleeps, a sleep apnea drug developer has secured a $192 million IPO after more than three years of eyeing a Nasdaq debut. Apnimed

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Finance & Markets

More from Friday 31 July →